Interpace Diagnostics will launch a public offering of nearly 6.3 million shares of its common stock in hopes of obtaining approximately $10.5 million in net proceeds, according to a filing with the SEC. The company intends to use the proceeds as working capital, as well as for general corporate functions, trade, payables and other obligations.
Interpace looks to obtain $10.5M in public offering
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.